Many treatments against cancer, such as TRAIL, aim to trigger a type of cell death known as apoptosis.
A team at IRB Barcelona, headed by Antonio Zorzano, has demonstrated that the protein TP53INP2 induces apoptosis in chemotherapy treatments.
La Opinión de Zamora has published an article summarising the days of oncological research organised by the United Association against Cancer Toro and its Alfoz (AUCCTA) and in which Angel R. Nebreda, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona) participated. During his talk, Nebreda commented: "We have come a long way but we still have a lot to do.But think about what we have achieved in the last 30 years, we know a lot more about how cancer develops and we have many more diagnostic methods, we know that there are hereditary cancers, that are genetic, and that they can be prevented by removing breasts and ovaries. We know that lung cancer is directly...
Tot Barcelona, e-notícies and El Plural have published an interview with Begoña Cánovas, a postdoctoral researcher at IRB Barcelona, who, thanks to a grant from "la Caixa", has been part of the team of researchers that detected the protein that fuels the survival of a type of breast cancer. "The day they gave me the first fellowship, I couldn’t believe it. I felt great and my parents jumped for joy when they found out. When you see all the applications, you feel like it's a lottery and you think you have no chance of winning, but it's worth trying, "said Cánovas.
Link to e-...
The newspaper "La Opinion" interviewed Angel R. Nebreda, ICREA researcher at IRB Barcelona, who will be participating in a conference on breast cancer on October 18 within the Health Forums of La Opinion and El Correo de Zamora. In this conference, he will be talking about his work in the lab on tumour formation and his efforts to unravel the mechanisms responsible for the transformation of normal tissue to a tumour.
Link to La Opinión
The projects address breast, lung, colon, prostate and melanoma cancer.
The newspaper “La Opinión de Zamora” has published an article devoted to breast cancer, one of the tumours most widely diagnosed in women in Spain and one of the most lethal.
The newspaper is organising a conference on breast cancer on 18 October, to which Angel R. Nebreda, ICREA researcher at IRBBarcelona, has been invited. The scientist will explain the breakthroughs achieved in basic research that can contribute to personalised treatments. Recently, Nebreda’s lab published a paper in the journal Cancer Cell reporting on a mechanism that prevents tumour...
El Punt Avui and La Vanguardia have published an article about the European Research Council (ERC) Proof of Concept grants. Five of them were given to centres belonging to the Barcelona Institute of Science and Technology (BIST), two corresponding to researchers Eduard Batlle and Angel R. Nebreda at IRB Barcelona.
Link to La Vanguardia: España, líder en la última convocatoria de ciencia europea (in Spanish)
Link to El Punt Avui:...
IRB Barcelona has been awarded two ERC PoC grants to optimise and validate tools with potential clinical applications.
Angel R. Nebreda’s project seeks to develop treatments to reduce the cardiotoxicity caused by chemotherapy.
Eduard Batlle’s project will build a biobank of mouse tumour organoids with the aim to contribute to the treatment of patients with advanced colon cancer.
Like many other great discoveries made in science, chance played an important role in the last article published in Cancer Cell by a team of researchers from the Signalling and Cell Cycle Laboratory at IRB Barcelona. "I think we were lucky, but we also knew how to take advantage of our luck," says the biochemist Begoña Cánovas, co-first author of the article, together with Ana Igea.
This success story started back in 2011 when Angel R. Nebreda’s Signalling and Cell Cycle Laboratory moved from CNIO (Madrid) to IRB Barcelona. Among many other things (from big machines to tiny gene copies), they brought with them some mice that were about to be discarded. They had been...
La Razón, Al Día, Cope, Medical News Today, Medical Xpress, among other national and international media, have published articles about the research led by Angel R. Nebreda, head of the Cell Signalling and Cell Cycle Lab at IRB Barcelona. This study identifies a new mechanism that contributes to the development of inflammation-associated colon cancer and proposes new therapeutic approaches.
Link to Al Día